Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Stock analysts at HC Wainwright reduced their FY2029 earnings estimates for Oncolytics Biotech in a research note issued on ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights.

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to Oncolytics Biotech Inc.’s fourth quarter and full ...

Oncolytics Biotech Inc (ONCY) reports significant advancements in cancer research despite increased net loss and leadership uncertainties.